Abstract:Background BAFF production is increased in IBD patients. However, the specific role of BAFF in IBD is still uncovered. This study aimed to investigate the expression and function of BAFF in experimental colitis and the potential mechanisms. Methods BAFF levels in the serum and colon tissues were measured by ELISA in DSS-induced colitis mice. Mouse-derived BAFF antibody was administered in DSS mice. The changes of body weight, disease activity index (DAI) scores, colon length, spleen weight, histopathological damage, inflammatory indicators, NF-κB signaling, and NLRP3 inflammasome were assayed in DSS mice and control. LPS-primed RAW264.7 cells and bone marrow derived macrophages (BMDMs) were treated with BAFF blockage and recombinant mouse BAFF. Inflammatory associated cytokines, NLRP3 inflammasomes and NF-κB signaling were detected among groups. Results BAFF production was elevated systemically and locally in colitis mice. BAFF blockade improved the body weight loss, DAI scores, colon length, spleen weight, and histopathological damage in colitis mice. Immunoflurescence analysis revealed that elevated macrophages in mucosal lamina propria were the primary source of BAFF in the colon. NLRP3 inflammasome and NF-κB signaling pathway activation were dramatically inhibited in DSS mice treated with BAFF blockage. In LPS-primed RAW264.7 cells/BMDMs, BAFF blockade decreased the activation of NLRP3 inflammasome (NLPR3, ASC, cleaved IL-1β, cleaved caspase 1) via inhibiting NF-κB signaling pathway. Moreover, LPS synergizes with BAFF to promote inflammatory factor secretion and expression of NF-κB signaling pathway in RAW264.7 cells. Conclusions These results suggested that BAFF blockade protected against colitis partially by relieving inflammation, inhibiting intestinal NLRP3 inflammasome and NF-κB signaling pathway from macrophages. BAFF plays an important role in inflammation regulation in IBD, thus providing a novel idea for further research on colitis and experimental evidences for novel potential therapeutic target in IBD.

Blockade of B-cell-activating Factor Suppresses Lupus-Like Syndrome in Autoimmune BXSB Mice

A Novel BAFF Antagonist, BAFF-Trap, Effectively Alleviates the Disease Progression of Systemic Lupus Erythematosus in MRL/lpr Mice

Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus

BAFF Promotes FLS Activation Through BAFFR-Mediated Non-canonical NF-κB Pathway and the Effects of CP-25.

Humanized BAFF Transgenic Mice Develop Autoimmune Manifestations

Targeting B and T lymphocyte attenuator regulates lupus disease development in NZB/W mice

BAFF suppresses IL-15 expression in B cells.

The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5+CD1dhiFcγRIIbhi Regulatory B-Cell Subset in Lupus.

BAFF-targeting Therapy, a Promising Strategy for Treating Autoimmune Diseases

Blockade of B-cell Activating Factor with TACI-IgG Effectively Reduced Th1 and Th17 Cells but Not Memory T Cells in Experimental Allergic Encephalomyelitis Mice

Therapeutic Effects of a Novel BAFF Blocker on Arthritis

Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice

A Benzenediamine Derivate FC-99 Attenuates Lupus Nephritis in MRL/lpr Mice Via Inhibiting Myeloid Dendritic Cell-Secreted BAFF

[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases].

Combination of TACI-IgG and Anti-Il-15 Treats Murine Lupus by Reducing Mature and Memory B Cells.

B Cell-Activating Factor and Its Targeted Therapy in Autoimmune Diseases.

B cell activating factor (BAFF) selects IL-10−B cells over IL-10+B cells during inflammatory responses

BAFF Blockade Attenuates DSS-Induced Chronic Colitis via Inhibiting NLRP3 Inflammasome and NF-κB Activation

BAFF antagonists designed by computer-aided drug design inhibited the interaction of BAFF with its receptors

Systemic Blockade of Probdnf Inhibited the Expansion and Altered the Transcriptomic Expression in CD3+B220+cells in MRL/lpr Lupus Mice

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients